Zrinka Tamburašev

[1] She joined the research institute of the pharmaceutical company PLIVA in 1957,[1] where she made several discoveries and patents in departments of microbiology, biochemistry, and biotechnology.

She began work on the synthesis of individual phases for the preparation of azithromycin, and the results of this research challenged the previous understanding of the macrocyclic ring of erythromycin as the bearer of the antibacterial activity of macrolides.

In 1974 her collaboration with Slobodan Đokić, Gabrijela Kobrehel, and Gorjana Lazarevski led to the development of azithromycin, an erythromycin derivative later established in the American market as Zithromax.

She is a co-author of patents that protected the preparation of oximes of erythromycin A and erythromycylamine, important intermediates in the synthesis of second-generation macrolide antibiotics (azithromycin, clarithromycin, roxithromycin, and dirithromycin).

Type: Grant Filed: January 10, 1975 Date of Patent: February 17, 1976 Assignee: Pliva, Pharmaceutical and Chemical Works Inventors: Gorjana Radobolja, Zrinka Tamburasev, Slobodan Djokic

From left to right - Gabrijela Kobrehel, Slobodan Dokic, Gorjana Radobolja-Lazarevski and Zrinka Tamburasev